These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2642629)

  • 21. Comparing the effects of milrinone and olprinone in patients with congestive heart failure.
    Dobashi S; Watanabe I; Nakanishi R; Hisatake S; Kiuchi S; Kabuki T; Oka T; Fujii T; Ikeda T
    Heart Vessels; 2020 Jun; 35(6):776-785. PubMed ID: 31865433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of positive inotropic phosphodiesterase III inhibitors.
    Honerjäger P
    Eur Heart J; 1989 Aug; 10 Suppl C():25-31. PubMed ID: 2553411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiology of phosphodiesterase inhibitors.
    Naccarelli GV; Goldstein RA
    Am J Cardiol; 1989 Jan; 63(2):35A-40A. PubMed ID: 2909995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous milrinone: therapeutic responses in heart failure.
    Braunwald E
    Am Heart J; 1991 Jun; 121(6 Pt 2):1937-8. PubMed ID: 2035423
    [No Abstract]   [Full Text] [Related]  

  • 25. Myocardial and vascular actions of milrinone.
    Colucci WS
    Eur Heart J; 1989 Aug; 10 Suppl C():32-8. PubMed ID: 2680495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
    Mehra MR; Ventura HO; Kapoor C; Stapleton DD; Zimmerman D; Smart FW
    Am J Cardiol; 1997 Jul; 80(1):61-4. PubMed ID: 9205021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.
    Tisdale JE; Patel R; Webb CR; Borzak S; Zarowitz BJ
    Prog Cardiovasc Dis; 1995; 38(2):167-80. PubMed ID: 7568905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
    Massie B; Bourassa M; DiBianco R; Hess M; Konstam M; Likoff M; Packer M
    Circulation; 1985 May; 71(5):963-71. PubMed ID: 3886191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
    Cuffe MS; Califf RM; Adams KF; Benza R; Bourge R; Colucci WS; Massie BM; O'Connor CM; Pina I; Quigg R; Silver MA; Gheorghiade M;
    JAMA; 2002 Mar; 287(12):1541-7. PubMed ID: 11911756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators.
    Teerlink JR; Jalaluddin M; Anderson S; Kukin ML; Eichhorn EJ; Francis G; Packer M; Massie BM
    Circulation; 2000 Jan 4-11; 101(1):40-6. PubMed ID: 10618302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
    Ribeiro JP; White HD; Arnold JM; Hartley LH; Colucci WS
    Am J Med; 1986 Nov; 81(5):759-64. PubMed ID: 3535490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of amrinone on myocardial energetics in severe congestive heart failure.
    Baim DS
    Am J Cardiol; 1985 Jul; 56(3):16B-18B. PubMed ID: 3161318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
    LeJemtel TH; Gumbardo D; Chadwick B; Rutman HI; Sonnenblick EH
    Circulation; 1986 Mar; 73(3 Pt 2):III213-8. PubMed ID: 3510777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
    Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
    Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inodilator therapy for heart failure. Early, late, or not at all?
    Remme WJ
    Circulation; 1993 May; 87(5 Suppl):IV97-107. PubMed ID: 8097971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.
    Cuffe MS; Califf RM; Adams KF; Bourge RC; Colucci W; Massie B; O'Connor CM; Pina I; Quigg R; Silver M; Robinson LA; Leimberger JD; Gheorghiade M
    Am Heart J; 2000 Jan; 139(1 Pt 1):15-22. PubMed ID: 10618557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some new positive inotropic agents.
    Andersson KE
    Acta Med Scand Suppl; 1986; 707():65-73. PubMed ID: 2874692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New knowledge on the subject of therapy in cardiac decompensation in the light of large trials].
    Camerini F; Perkan A; Sinagra G; Di Lenarda A; Pinamonti B; Zecchin M
    Ann Ital Med Int; 1994 Oct; 9 Suppl():68S-77S. PubMed ID: 7857761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
    DiBianco R; Shabetai R; Kostuk W; Moran J; Schlant RC; Wright R
    N Engl J Med; 1989 Mar; 320(11):677-83. PubMed ID: 2646536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.